Bio-Techne and Wyss Center Join Forces for 3D Multiomics
The collaboration between Bio-Techne Corporation (NASDAQ: TECH) and the Wyss Center for Bio and Neuroengineering marks an exciting advancement in automated 3D multiomics technology, specifically aimed at enhancing spatial biology research. This partnership not only simplifies RNA and protein detection but also addresses the complexities associated with traditional methods used in studying 3D tissue specimens.
Innovative Approach to Research in 3D
This groundbreaking initiative seeks to automate the multiomic analysis of 3D samples, which has historically been a challenging endeavor. By leveraging advanced methodologies, the new system aims to improve the efficiency of experiments allowing researchers to gain deeper insights into the complexity of biological processes. With this innovation, the project emphasizes reducing obstacles that typically hinder researchers, notably the cumbersome manual processes prevalent in many laboratories today.
Redefining Biomedical Research
In today's scientific landscape, there is a pressing need for new approaches that can reduce the reliance on animal testing. The collaboration between Bio-Techne and Wyss Center not only seeks to advance this objective but also pioneers New Approach Methodologies (NAMs). One such methodology includes organoids, which simulate human organs in vitro, thereby minimizing ethical concerns and allowing for more predictive modeling in preclinical research.
Dr. Stéphane Pages from Wyss Geneva emphasized the significance of their work, stating that the advancement of 3D multiomics has the potential to deeply transform our understanding of biological systems. With this partnership, they aim to make these powerful tools widely accessible to researchers around the globe.
Enhancing Drug Discovery and Diagnostics
Bio-Techne's robust portfolio of spatial biology technologies has already made significant strides in unlocking vital information in two-dimensional studies. The move to integrate these capabilities into three-dimensional frameworks opens unprecedented avenues for research. This shift is set to optimize drug discovery processes, helping to streamline the development of new treatments by elucidating tissue structures and cellular interactions more clearly.
As part of its broader mission to enable impactful research, Bio-Techne’s partnership with Wyss Geneva positions it favorably within the life science industry. The capabilities emerging from this collaboration could lead to significant breakthroughs in not only biomedical research but also in diagnostic advancements, ultimately transforming the landscape of healthcare.
Commitment to Progress and Innovation
Bio-Techne’s President of the Diagnostics and Spatial Biology Segment, Matt McManus, noted that this collaboration reinforces the company’s commitment to fostering innovation through strategic partnerships. By integrating their expertise in the realms of RNA and protein detection with Wyss Geneva's cutting-edge capabilities in 3D translational research, they are on track to unlock new possibilities in preclinical modeling.
Bio-Techne strives to enhance the accessibility of next-generation research tools, gradually minimizing the complexities often associated with spatial biology technologies. With this partnership, they are set to lead the way in cutting-edge research tools that allow scientists to explore biological phenomena in a more spatially accurate manner.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is recognized as a premier global life sciences company dedicated to providing innovative tools and bioactive reagents essential for both research and clinical diagnostics. With an extensive portfolio of products, Bio-Techne’s contributions support in-depth scientific investigations into the mechanisms of disease and their progression. The corporation has experienced substantial growth, generating over $1.2 billion in net sales recently, with a commitment to providing top-notch research resources to scientists worldwide.
About the Wyss Center for Bio and Neuroengineering
The Wyss Center for Bio and Neuroengineering is an innovative, nonprofit organization dedicated to developing technologies aimed at restoring neural functions. Based in Geneva, this center combines expertise from fields such as AI and bioengineering to create solutions for brain and mental health disorders. The Wyss Center actively collaborates with various partners, striving to accelerate advancements in neurotechnology to improve therapeutic options.
Frequently Asked Questions
What is the focus of the Bio-Techne and Wyss Center collaboration?
The collaboration aims to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, enhancing spatial biology research.
How does this partnership impact preclinical research?
This partnership seeks to reduce reliance on animal testing and improve predictive modeling in biomedical studies through advanced techniques like organoids.
What are the potential benefits of automated multiomics?
Automated multiomics can accelerate drug discovery and enhance diagnostic development by providing more nuanced insights into the complexities of biological systems.
Who are the key figures involved in this project?
Dr. Stéphane Pages from Wyss Geneva and Matt McManus of Bio-Techne are key figures advocating for the advancements in spatial biology presented by this collaboration.
How has Bio-Techne’s financial growth influenced this collaboration?
Bio-Techne's significant revenues allow it to invest in transformative partnerships and advanced technologies, ultimately facilitating innovation in the life sciences sector.
